Healthcare, Healthtech & Medtech

11 Tribes Ventures Fund II is a $46 million early-stage venture capital fund launched in April 2025 by Chicago-based 11 Tribes Ventures. Building upon the success of its inaugural fund, Fund II aims to invest in approximately 30 companies over the next three years, with nine investments already made. The fund is distinguished by its "capital and care" philosophy, emphasizing deep, personal relationships with founders. 11 Tribes dedicates significant time to understanding a founder's personal journey, focusing on their well-being alongside business metrics. A unique aspect of Fund II is its commitment to founder resilience: 2% of invested capital is allocated as non-dilutive grants to support founders' mental, emotional, and organizational health through coaching, counseling, and therapy. Fund II positions 11 Tribes as the lead investor in most funding rounds, targeting capital-efficient businesses with sustainable growth models and exit opportunities between $75 million and $250 million.

ABC Impact Fund II is the second flagship private equity fund managed by ABC Impact, a Singapore-based investment firm focused on generating measurable social and environmental impact across Asia. Launched in August 2023, the fund achieved a final close in April 2025, raising over USD 600 million—doubling the size of its predecessor. The fund secured commitments from a diverse group of global and regional investors, including Temasek, Temasek Trust, the Asian Development Bank (ADB), Mapletree Investments, SeaTown Holdings, a Southeast Asian sovereign wealth fund, a U.S. family office, and various ultra-high-net-worth individuals. The fund targets four key sectors: clean energy and climate resilience, inclusive finance and digital access, healthcare and education, and sustainable food systems. It provides growth capital to innovative, commercially viable companies that contribute to achieving the United Nations Sustainable Development Goals (SDGs). Representative investments include Aye Finance in India, Tekoma Energy in Japan, and DCDC Kidney Care, a leading dialysis provider serving underserved populations in India. ABC Impact implements a disciplined impact measurement and management framework, aligned with international standards such as the Principles for Responsible Investment and the Operating Principles for Impact Management. With total assets under management exceeding USD 900 million, the firm continues to scale private capital solutions that support a more inclusive and sustainable future for Asia.

ARCH Venture Fund VIII is an early-stage venture capital fund managed by ARCH Venture Partners, focused on disruptive biotechnology, life sciences, energy, and materials companies. The fund closed above $400 million in August 2014, significantly exceeding its $250 million target. ARCH Venture Partners specializes in commercializing breakthrough technologies developed at academic institutions, national laboratories, and corporate research groups, co-founding companies alongside leading scientists and entrepreneurs.

Adams Street Partners has successfully closed its inaugural European venture capital fund, the Adams Street European Venture Fund 2023, securing over €270 million in commitments. This amount significantly surpasses the initial target of €200 million, reflecting strong investor confidence in Europe’s growing startup ecosystem. The fund seeks to capitalize on Adams Street’s global investment expertise to identify and back innovative early-stage companies across the continent. The fund focuses primarily on the technology and healthcare sectors. Its capital is deployed with 70% allocated to primary commitments in European venture funds, and the remaining 30% toward co-investments and secondary transactions. This hybrid model provides exposure to a diverse set of opportunities while maintaining flexibility to support breakout companies directly. Leveraging decades of venture experience and a vast global network, Adams Street aims to generate long-term value through a disciplined approach. With deep relationships across Europe’s VC landscape, the firm is well-positioned to gain access to top-tier opportunities and help entrepreneurs scale their businesses.

Adams Street Private Equity Navigator Fund LLC is an evergreen, closed‑end interval fund registered under the Investment Company Act of 1940 in April 2025. Managed by Adams Street Advisors, LLC, it continues the investment program of its predecessor Cayman Islands fund, offering investors broad access to global private markets strategies. The Fund’s objective is to deliver long‑term capital appreciation via a diversified portfolio comprised of primary and secondary private equity fund interests, direct equity and debt investments in private companies (including growth equity, co‑investments, and private credit), along with liquid high‑quality assets to maintain operational flexibility and periodic liquidity. As an interval fund, it balances the illiquid nature of private markets with investor access through periodic repurchase offers, which provide limited liquidity alongside private market exposure. The structure includes multiple share classes—Class S, D, I, and M—each with different fee and expense structures. The Fund seeks exemptive relief to allow this multi‑class structure, early withdrawal charges, and asset‑based distribution/service fees, aligning with standard interval fund frameworks that support investor access and operational resilience.

Advent International GPE XI is the eleventh flagship global private equity fund from Advent International, a leading global private equity firm. The fund is targeting $26 billion in commitments, surpassing its predecessor GPE X, which closed at $25 billion in 2022. GPE XI continues Advent's strategy of investing in control buyouts of companies across various sectors and geographies. The fund focuses on five core sectors: business and financial services, healthcare, industrial, consumer, and technology. Advent seeks to partner with management teams to drive revenue growth, operational improvements, and strategic expansion. The firm's approach involves identifying companies with strong potential and working closely with them to achieve sustainable growth. Geographically, GPE XI aims to invest primarily in North America and Europe, while also exploring opportunities in Asia and Latin America. Advent's global presence and local expertise enable it to identify and capitalize on investment opportunities across diverse markets.

AlpInvest Co-Investment Fund IX (ACF IX) is the ninth iteration of AlpInvest Partners' flagship co-investment strategy. Managed by AlpInvest Partners, a subsidiary of The Carlyle Group, the fund focuses on providing investors with access to private equity buyouts by co-investing alongside leading private equity firms. ACF IX aims to capitalize on attractive investment opportunities in the mid-market segment, leveraging AlpInvest's extensive network and experience in the private equity space. The fund has successfully raised $4.1 billion, surpassing its predecessor's $3.5 billion close in 2021. ACF IX attracted commitments from 185 global investors, including pension funds, asset managers, and family offices. The fund's strategy involves investing in whole-company buyout transactions and equity stakes across various industry sectors worldwide. By focusing on mid-market deals, ACF IX seeks to achieve favorable entry valuations, often at 15% to 20% discounts compared to peak-period prices. AlpInvest's co-investment platform has a track record of over 400 equity co-investments, committing more than $19 billion over the past 25 years. The firm's approach emphasizes building long-term partnerships with top-tier private equity sponsors, enabling access to high-quality deal flow and efficient execution. ACF IX continues this tradition, aiming to deliver attractive risk-adjusted returns to its investors through a diversified portfolio of co-investments.

Ansor, a UK-based private equity firm, has successfully closed its second fund, Ansor Fund II, at the hard cap of £250 million, nearly doubling the size of its inaugural fund raised in 2019. The fund was significantly oversubscribed, attracting a carefully curated group of high-quality limited partners, including leading US-based endowments and blue-chip European investors. Ansor Fund II will continue the firm’s strategy of building high-quality assets through rapid “ground-up” buy-and-build consolidation within fast-growing yet fragmented subsectors. The firm targets resilient, EBITDA-positive businesses that can undergo multiple value inflections through its precision-engineered value creation approach. Led by founding partners Edward Ainsworth, Peter Marson, and Peter Strafford, Ansor leverages over 20 years of experience creating businesses from scratch within the UK SME ecosystem. Since transitioning to a private equity model in 2019, the firm has refined its systematic investment approach and expanded its team and tech infrastructure.

Apax XI is a private equity buyout fund that will continue to focus on investment opportunities across the Tech, Services, Healthcare, and Internet/Consumer sectors. This sector-focused strategy will guide the fund's target investments, allowing for the identification of businesses with growth potential within these specific sectors. Additionally, the fund has already committed 15% of its capital across five investments, three of which are corporate carveouts and one is a day-one combination of two businesses. This reflects the fund's operationally intensive approach to investing and its focus on enabling companies to realize their full potential. The fund is located in London, United Kingdom. The fund has received commitments from a diverse set of new and returning investors, including public and private pension funds, sovereign wealth funds, fund of funds, insurance companies, endowments, and charitable foundations. This diverse investor base reflects the fund's appeal to a wide range of institutional investors. Apax XI is a dual-currency fund (USD and EUR).

The Apollo S3 Equity & Hybrid Solutions Fund I (ASEHS) is a buyout fund managed by Apollo Global Management, headquartered in New York, NY. The fund is part of Apollo's Sponsor and Secondary Solutions (S3) platform, which provides flexible capital solutions across the yield, hybrid, and equity spectrum to asset managers and limited partners. ASEHS focuses on acquiring secondary interests in private equity funds and providing liquidity solutions to general partners and limited partners. The fund aims to capitalize on the growing demand for liquidity in the private markets by offering innovative financing options, including net asset value (NAV) loans and structured equity solutions.​ With a fund size of $5.4 billion, ASEHS seeks to deliver attractive risk-adjusted returns by investing in a diversified portfolio of secondary transactions. The fund leverages Apollo's extensive network and expertise in private equity, credit, and real assets to identify and execute complex deals. By providing tailored liquidity solutions, ASEHS supports the evolving needs of private market participants and contributes to the overall efficiency and resilience of the alternative investment ecosystem.​ ASEHS targets a broad range of sectors through its investments in secondary interests of private equity funds. These sectors include, but are not limited to:​ - Technology - Healthcare - Consumer Goods - Industrial Manufacturing - Financial Services​ The fund's diversified approach allows it to capitalize on opportunities across various industries, depending on the underlying assets of the secondary interests acquired. ASEHS primarily focuses on investments in North America and Europe, reflecting the regions where Apollo has a strong presence and deep market knowledge. The fund may also consider opportunities in other developed markets, depending on the attractiveness of the secondary transactions and the quality of the underlying assets.​

The Ares Specialty Healthcare Fund is a specialized direct‑lending vehicle managed by Ares Management, formed to provide flexible capital solutions to companies operating across the specialty healthcare ecosystem. It focuses on industries such as pharmaceuticals, biotechnology, medical technologies and diagnostics, specialist healthcare services and healthcare IT where companies often face constraints accessing traditional bank financing or need transformational capital. The fund is structured to invest across the capital structure — from first‑ and second‑lien senior secured loans, to mezzanine debt, preferred equity and minority equity stakes — enabling the team to tailor solutions to companies undergoing growth or transformation. It targets businesses in North America and Europe and is backed by a dedicated investment team and industry advisory board with deep healthcare operating expertise. Recognising enduring structural trends — an aging population, innovation in diagnostics and medtech, increasing digitalisation of healthcare and shifting service models — the fund seeks to invest in companies with resilient demand and growth potential. It aims to deliver both defensive characteristics (i.e., non‑cyclical healthcare demand) and meaningful upside from innovation and transformation in the healthcare value chain. By partnering with firms across the healthcare spectrum — from device manufacturers and diagnostics players to niche specialty services and healthcare IT platforms — the fund aims to fill a financing gap and support businesses that are scaling, executing roll‑ups or transforming their offerings. The strategy leverages Ares’ broader credit platform and healthcare expertise to structure creative, non‑dilutive capital solutions in an increasingly competitive healthcare financing environment.

Aruwa Capital Fund II is a gender-lens, early-growth equity fund managed by Aruwa Capital Management, a Lagos-based, female-founded and led private investment firm. The fund seeks to empower underrepresented founders and address funding gaps for growth-stage companies in West Africa, especially those creating scalable solutions in essential sectors. Building on the success of its inaugural fund, Aruwa Capital Fund II targets high-impact businesses that generate both financial returns and measurable social value. The fund focuses particularly on companies that promote inclusive economic development and improve livelihoods, with a strong emphasis on enhancing opportunities for women as business owners, consumers, and employees. The fund has already backed two companies—Yikodeen, a safety boots manufacturer, and a fast-casual restaurant chain—selected for their alignment with Aruwa’s mission of inclusive growth and economic empowerment. With strong investor demand, Aruwa is considering increasing the fund’s hard cap from its original $40M target to $50M or even $60M.

The Autism Impact Fund (AIF) is venture capital fund that focuses on investing in startups in the neurodiversity space. Funded by institutional LPs such as investment firms Fairfield-Maxwell and Ferd, AIF aims to become "the investment and innovation arm of the autism community." With an initial fund of $60 million, AIF has already invested in 12 startups in its portfolio (as of April 2024). The fund's target investments are diverse and include sectors such as life sciences and data- and tech-enabled services. It also expands beyond the U.S., with investments in German consulting firm Auticon and British telehealth platform Healios. AIF plans to diversify further, broadening its scope to include behavioral health data-driven platforms, innovative healthcare solutions, and value-based care frameworks. The fund also invests in addressing autism comorbidities, such as gastrointestinal issues, and focuses on independence in areas like employment, financial independence, and housing. AIF's approach to investment reflects rising awareness about autism as a spectrum that affects individuals across their lifespans, not just during childhood. The fund is looking at potential investments in AI and other technologies while addressing the broader societal costs of autism. With a global focus, AIF partners with startups like Mentra and Genial Care to support the neurodiversity space, reflecting the increased momentum and creation of companies in this field.

Axcel Elevate I is a new lower mid‑market buyout fund launched by Axcel, closing in November 2025 at a €459 million hard cap following an oversubscribed fundraising round. The commitments came from a mix of institutional backers — including pension funds, funds-of-funds, foundations, and family offices — many of whom were existing supporters of Axcel, underscoring strong investor confidence in the new vehicle’s strategy.The fund focuses on smaller buyout targets across the Nordic region, aiming at companies that lie beneath the threshold of traditional mid‑market funds. The target sectors include technology, business services & industrials, and healthcare, leveraging Axcel’s deep sector expertise and long-standing track record in these verticals.Elevate I is fully integrated into Axcel’s broader platform: the dedicated Elevate team works alongside the firm’s more than 30 investment professionals, supported by investor relations, compliance, sustainability and operations functions. This integration allows the fund to apply Axcel’s proven value‑creation methodology — including buy‑and‑build strategies, digitalisation, operational improvement and sustainability initiatives — adapted to the lower mid‑market segment.

The latest vehicle from BC Partners, Fund XII, marks the firm’s 12th flagship buy‑out fund and is structured to capitalise on its proven track record in upper mid‑market investments across Europe and North America. With a target of roughly €5‑6 billion in commitments, the fund seeks to leverage BC Partners’ deep operational platform, sector expertise and global sourcing capabilities to back companies with strong growth potential and resilient business models. The investment strategy emphasises “defensive growth” – targeting market‑leading companies in sectors such as TMT, Services & Industrials, Healthcare and Food that exhibit predictable cash flows, margin resilience and multiple avenues for value creation. The fund team will partner with proven management teams and seek to drive organic expansion, internationalisation, M&A‑led growth and operational improvement. Geographically, Fund XII will focus primarily on Europe and North America, drawing on BC Partners’ well‑established trans‑Atlantic platform and track record of investing across these regions. The firm believes that the upper mid‑market segment offers a compelling combination of deal flow quality, exit optionality and relative insulation from large‑cap competition. While the fund is still in fundraising, BC Partners is positioning Fund XII to exploit a market environment in which exit activity is picking up, valuations are re‑adjusting and disciplined buy‑out vehicles can deliver attractive returns. The firm emphasises operational value creation and seeks to partner with businesses that can benefit from BC Partners’ global resources, local networks and sector expertise. In doing so, Fund XII aims to deliver long‑term, risk‑adjusted returns for its limited partners.

BPEA Private Equity Fund IX is the latest flagship fund from EQT Private Capital Asia, aiming to raise $12.5 billion, with a hard cap set at $14.5 billion. Launched in August 2024, the fund continues the strategy of its predecessor, BPEA VIII, focusing on control-oriented, large-cap buyouts across the Asia-Pacific region. The fund leverages EQT's pan-Asian coverage and bottom-up investment approach to identify value and sector trends across diverse markets. The fund targets investments in sectors benefiting from structural and secular tailwinds, including technology, services, healthcare, industrial services, and technology services. With a focus on scalable market leaders, BPEA IX aims to construct a diversified portfolio of 18 to 22 companies, each with strong growth potential and defensible market positions. BPEA IX plans to make 4 to 6 investments per year, with average equity investments of $300 million and targeting companies with enterprise values ranging from $500 million to $2 billion. The fund's strategy is designed to capitalize on favorable demographics, professionalization of under-managed assets, and corporate governance reforms across the region.

Bain Capital Asia Fund V is a 2023 vintage buyout fund managed by Bain Capital. The fund is located in Hong Kong and invests in Asia. Bain Capital's fifth Asia-focused fund has exceeded its initial target of $5 billion and has raised around $7.1 billion from global investors. The firm, which started fundraising in the second half of last year, aims to complete the exercise in the coming weeks. Bain Capital's new Asia fund will focus heavily on Japan, where it has landed marquee deals such as the $18 billion buyout of Toshiba Corp’s memory chip business.

Bain Capital Fund XIV marks the latest flagship private equity vehicle launched by Bain, achieving a successful raise of USD 14 billion, surpassing its initial USD 10 billion target. The fund is anchored by both external investors (USD 11.8 billion) and Bain‑affiliated entities, which retain a leading investor role. This oversubscription underscores the confidence in Bain’s strategy and capacity to execute at scale. Structured across U.S. (Delaware) and Luxembourg vehicles, Fund XIV supports Bain’s global investment ambitions. The firm integrates its capital across geographies and sectors, leveraging its operational platform and deep domain expertise. The fund benefits from Bain’s global infrastructure, which includes over 330 professionals globally, and a dedicated 90‑member portfolio group focused on digital transformation, supply chain, and talent development. In its investment approach, Fund XIV emphasizes operational value creation over financial engineering. Bain estimates that about 80 % of value across its prior decade of portfolio performance was driven by operational improvements—reflecting its hands‑on, transformational approach in complex environments. The fund will compete in core sectors such as consumer, healthcare, industrials, services, and technology, deploying significant equity capital into fewer, well‑chosen companies. With greater scale and ambition, Fund XIV positions Bain to broaden its platform and generate durable value creation even in competitive markets. The fund will look for investments where Bain’s sector expertise, cross‑platform capabilities, and global insights can make a differentiating impact. Its success will further cement Bain’s position among the world’s leading private equity firms.

Banner Capital Fund I is a $400 million multi-asset continuation fund established by Banner Capital Management to acquire interests in eight of its pre-fund portfolio companies. This strategic recapitalization, led by Hamilton Lane, aims to provide additional time and capital to these businesses, while offering partial liquidity to early investors and crystallizing performance. The fund's structure allows Banner Capital to continue supporting its portfolio companies' growth trajectories, leveraging its expertise in the lower middle market. By consolidating these assets into Fund I, Banner ensures a focused approach to value creation, aligning the interests of new and existing investors. As of the closing of this transaction, Banner Capital reports $653 million in assets under management, reflecting its commitment to nurturing founder- and family-owned businesses across the Western United States.

Banner Capital Fund II is a lower middle market buyout fund launched by Banner Capital Management, LLC, with a target size of $200 million. The fund focuses on investing in founder- and family-owned businesses across the Western United States, particularly in the Intermountain West region. Banner Capital aims to support these companies by providing partnership capital to facilitate growth and operational improvements. The fund has already held a preliminary closing to facilitate its first platform investment in Western Pavement Services, a company focused on asphalt maintenance in the Western U.S. This initial investment underscores Banner Capital's commitment to its investment strategy and regional focus. The Larry H. & Gail Miller Family Foundation, along with other legacy limited partners, participated in this initial closing, demonstrating strong investor confidence in the fund's approach. Banner Capital Fund II continues the firm's dedication to investing in the industrial, services, consumer, and healthcare sectors. With a traditional first closing anticipated in the fourth quarter of 2025, the fund is poised to build a diversified portfolio of lower middle market companies, leveraging Banner Capital's experience and network to drive value creation.

The Beyond Capital Partners Fund III, a 2023 vintage private equity fund managed by Beyond Capital Partners GmbH, closed at the hard cap of EUR 180 million in April 2024. The fund has secured capital commitments from institutional limited partners and fund-of-funds from continental Europe. Beyond Capital Partners and Beyond Family & Friends also provide more than ten percent of the fund volume, ensuring alignment of interests with limited partners. The fund's investment strategy focuses on the lower-mid-market segment, targeting companies in the DACH region with enterprise values of up to EUR 50 million. The fund has already made two platform investments and a first add-on, demonstrating its commitment to the region and the segment. With a team of fifteen professionals, the fund aims to continue its successful investment strategy, building on its experience from previous transactions. Beyond Capital Partners places a strong emphasis on ESG as an additional value driver. As a SFDR 8+ Fund, the fund is dedicated to creating value through focusing on ESG-related elements. The fund was supported in its fundraising efforts by Triago S.A. as a placement agent and by Clifford Chance as a legal advisor. Specifically, the fund targets majority shareholdings in profitable Mittelstand companies in the DACH region with a focus on asset-light business models in sectors such as B2B services, IT services, software, healthcare & well-being, lifestyle, and entertainment. This underscores the fund's commitment to investing in businesses that align with its strategic vision and value creation objectives."

Blackstone Capital Partners Asia III is the third edition of Blackstone’s Asia-focused buyout strategy, targeting control and significant minority investments across high-growth sectors in the Asia-Pacific region. The fund launched fundraising in September 2024 and quickly attracted strong global institutional interest, building on Blackstone’s proven track record in the region. As of October 2025, the fund has reached its $10 billion target and is on track to close at its $12.9 billion hard cap by Q1 2026. Approximately 90% of existing LPs from prior Asia funds have recommitted, increasing their allocations by an average of 30%. The strong backing reflects confidence in Blackstone’s historical performance, particularly the 41% net return and 80% capital returned from Fund II. Geographically, India and Japan remain core to the strategy. In previous Asia funds, India accounted for 31% of capital deployed, followed by 22% in Japan and 9% in Australia. Fund III will pursue broader regional diversification, adapting to evolving market dynamics and tapping into emerging opportunities across the wider Asia-Pacific landscape. Despite macro headwinds such as high interest rates and a muted exit environment, Blackstone and other top-tier global firms continue to raise mega-funds by leveraging strong brands, deep operational teams, and global scale. Asia-Pacific’s long-term secular growth, demographic trends, and economic transformation continue to make it a compelling region for private equity deployment.

BlueFive Reef Private Equity Fund I is a $2 billion closed‑end buyout vehicle launched by BlueFive Capital and registered with the Abu Dhabi Global Market (ADGM), marking one of the largest private equity raises in the Gulf region. The fund targets both majority and minority stakes in high‑growth, large‑cap businesses across the GCC—specifically in healthcare, technology, hospitality, aviation, and industrial sectors—partnering with strong regional founders to elevate local champions toward global competitiveness. Positioned to leverage the Gulf’s economic diversification and strategic East‑West gateway role, Reef I seeks to capitalize on evolving market dynamics as governments broaden their non‑oil economies, with geographic focus on GCC countries and potential expansion into Asia and Latin America as aligned with BlueFive’s broader strategy.

BluePeak Private Capital Fund II (BPCF II) is a pan-African private credit fund launched by BluePeak Private Capital, an alternative asset management firm established in 2019. The fund aims to raise $250 million to provide flexible credit solutions to underserved mid-sized businesses across Africa, addressing the persistent financing gap that hinders their growth. BPCF II focuses on delivering impact-driven investments while offering investors superior risk-adjusted returns. The fund targets strategic sectors such as manufacturing, pharmaceuticals, logistics, and financial services—industries pivotal to deepening local value chains and fostering industrial clusters. With a strong emphasis on gender inclusion, BPCF II is 2X Challenge qualified, promoting women's economic empowerment as a core objective. The fund integrates sustainability considerations throughout its investment process, prioritizing resilience, inclusive growth, and long-term value creation. In its first close, BPCF II secured $80 million in commitments from leading European Development Finance Institutions (DFIs), including British International Investment (BII), FMO, Swedfund, and the Swiss Investment Fund for Emerging Markets (SIFEM). These commitments underscore the DFIs' confidence in BluePeak's strategy to combine performance with impact, mobilizing capital to Africa's underserved mid-market segment.

CVC Credit Partners European Direct Lending Fund IV (“EUDL IV”) marks a significant milestone in the growth of CVC’s private credit platform. With €10.4 billion raised across the fund and parallel vehicles, this fourth iteration of the European direct lending strategy represents a substantial increase from its predecessors, reflecting strong investor appetite for sponsor-backed private credit solutions in Europe. The fund benefits from CVC’s deep market presence and long-established track record in the region. The fund targets private equity-sponsored mid-to-large cap businesses across Europe, offering flexible, tailored lending solutions. CVC leverages the strength of its Private Equity platform and pan-European credit expertise to source proprietary deals and deliver comprehensive financing packages. EUDL IV has already committed capital to over 30 transactions, including high-profile deals such as KKR’s acquisition of Immedica Pharma and Cinven’s purchase of idealista. EUDL IV’s investment approach emphasizes senior secured lending, focused on risk-adjusted returns and capital preservation. The fund’s scale and execution capacity enable it to lead or anchor transactions, positioning CVC as a trusted partner to sponsors and borrowers alike. Its strategy also supports complex financings such as take-privates, platform acquisitions, and recapitalizations. CVC Credit continues to grow its private credit footprint, now managing over €18 billion across Direct Lending and Capital Solutions. With strong tailwinds in the European private credit market and increasing disintermediation from traditional banks, EUDL IV is well-positioned to capture market share and deliver attractive risk-adjusted returns for its global institutional investor base.

The Calm / Storm 2 fund is a dedicated early‑stage venture capital vehicle established by Calm/Storm Ventures out of Austria, designed to invest across the health‑tech and wellbeing space in Europe. With a final close around €30 million, the fund seeks to partner with startup founders driving meaningful innovation in prevention, diagnostics, digital health tools and infrastructure for large healthcare systems. Unlike many health‑tech investors who wait until later stages, this fund is committed to getting in very early—pre‑seed, seed and occasionally post‑seed—taking meaningful stakes and often leading rounds alongside a strong network of co‑investors. It emphasises partnership, mentorship and ecosystem building as much as capital. Diversity and purpose are core to its philosophy: Calm/Storm emphasises founding teams from under‑represented backgrounds, and invests in areas often overlooked (e.g., fertility, mental health, sexual wellness, chronic conditions) where innovation can have disproportionate impact. The fund thus aims for both financial return and societal benefit. The fund will deploy capital across primarily European companies (with at least ~75% of investees registered in Europe at the time of investment) and aims for average ticket sizes of around €500 k, roughly double that of its predecessor fund. It expects to lead or co‑lead 30‑40 investments, leveraging its community of founders and ecosystem of LPs to create access, scale and value.

Carlyle Japan Partners V (CJP V) is The Carlyle Group's fifth Japan-focused buyout fund, achieving a final close at ¥430 billion (approximately $2.8 billion USD), marking it as the largest Japan-focused buyout fund to date. This fund represents a significant increase of nearly 70% over its predecessor, reflecting strong investor confidence and demand from both domestic and international limited partners. CJP V continues Carlyle's established strategy of investing in upper middle-market opportunities within Japan. The fund focuses on sectors such as Technology, Media, and Telecom (TMT); Consumer, Retail, and Healthcare (CRH); and General Industries (GIG). Investment approaches include succession transactions, corporate carve-outs, and strategic take-private deals, aiming to support companies through transitions and growth phases. With over two decades of experience in the Japanese market, Carlyle leverages its local expertise and global resources to identify and nurture investment opportunities. The firm's commitment to Japan is underscored by its plan to expand its local investment team, ensuring robust support for portfolio companies and sustained value creation for investors.

Cathay Innovation Fund III is a €1 billion global venture capital fund launched by Cathay Innovation to invest in startups driving the sustainable transformation of industries and society. The fund focuses on application-layer AI companies across sectors such as digital health, fintech, consumer applications, and energy/mobility. It targets Series A to late-stage startups, with investment amounts ranging from €5 million to €80 million. Fund III is backed by institutional investors and multinational corporations, including Sanofi, TotalEnergies, and BNP Paribas Cardif. The fund aims to support companies that are accelerating the sustainable transformation of industries and society through next-generation technologies, business models, and platforms. Cathay Innovation leverages its global investment platform and extensive corporate ecosystem to provide startups with access to new markets and strategic partnerships. The fund integrates sustainability into every step of the investment cycle to measure, track, and maximize the impact of startups while helping entrepreneurs build more responsible, resilient businesses. Cathay Innovation has a strong investment track record, having backed over 120 early-stage startups across Europe, Asia, and North America. Of these, 19 have become unicorns, including Chime Bank, Wallbox, Ledger, and Glovo. Fund III continues this legacy by investing in companies with high growth potential and the capacity to expand internationally, aiming to empower businesses to lead the large markets of the future.

Charlesbank Equity Fund XI is the eleventh flagship private equity fund from Charlesbank Capital Partners, currently in the market with a $4 billion target. Building on the success of its predecessor, Fund X, which closed at $3.75 billion, Fund XI continues the firm's strategy of investing in North American middle-market companies across sectors such as industrials, technology, and healthcare. The fund aims to acquire control positions in companies with enterprise values ranging from $150 million to $3 billion. Charlesbank seeks businesses with strong free cash flow yields and durable competitive advantages, often engaging in transactions like growth capital investments, carve-outs, and executive-led buyouts. Charlesbank's investment approach emphasizes rigorous due diligence and operational improvements. The firm leverages its deep sector expertise and a team of approximately 60 investment professionals to identify and grow portfolio companies, aiming to deliver superior returns for its investors.

Churchill Asset Management, the Nuveen affiliate focused on private capital, has held the final close of Churchill Co-Investment Fund II at its $1.5 billion hard cap—almost 3.5 times the size of its 2020 predecessor. The vehicle was heavily oversubscribed, attracting commitments from a globally diversified roster of sovereign wealth funds, public and corporate pensions, insurers, funds-of-funds, family offices and, notably, a growing private-wealth channel that now supplies roughly 20 % of the capital base. Building on Churchill’s long-standing role as an LP in more than 280 PE funds, Fund II will provide equity co-investments alongside top-tier buy-out sponsors in U.S. middle-market companies. Typical equity tickets range from $20–50 million (with flexibility down to $30 million for smaller deals) and target businesses generating EBITDA of $15–75 million. Sector-wise, Churchill is prioritising B2B software, tech-enabled and business services, professional services and healthcare, where recurring revenue, defensible market positions and cash-flow visibility are prevalent. Roughly 30 % of the fund has already been deployed across 25 such investments, demonstrating strong early momentum despite a slower exit environment for private equity more broadly.

Clarion Capital Partners, LLC has closed its fourth private equity fund, Clarion Investors IV, L.P. with $677 million in total capital commitments. The Fund seeks long-term investment outperformance primarily through partnering in buyouts of lower-middle market companies. The fund exceeded its fundraising target of $600 million and marks Clarion’s second oversubscribed fund in a row. Clarion focuses on making primarily control investments in a diversified portfolio of lower middle-market companies generating $7.5-30.0 million of EBITDA. The firm seeks to invest in growth companies in sectors such as Media, Entertainment & Technology, Financial Technology & Services, Business, Healthcare & Industrial Services, and Consumer. In addition to the private equity business, Clarion established a credit business focused on structured corporate credit in 2018, which will continue to be led by Robert Klein, President and Chief Investment Officer of Structured Credit. Clarion has experienced tremendous growth since its founding in 1999 and has generated top-quartile returns in its first two funds. The firm was recognized by Pitchbook as the number two firm out of 414 buyout private equity firms with track records across multiple vintages. In addition, GCI Publishing announced in March that the firm was chosen as a 2024 Top 50 Private Equity Firm in the Middle Market. The fund was raised with the help of Paul, Weiss, Rifkind, Wharton, & Garrison LLP as legal counsel. The fund invests in the U.S..

Comvest Credit Partners VII is a a direct lending fund focused on traditional first lien and asset-based loans for niche sponsor, non-sponsor, and non-traditionally sponsored borrowers in North America. The fund is located in West Palm Beach, Florida. - Financial Profile of target: EBITDA greater than $7.5 million, with exceptions for recurring revenue, specialty finance, high growth or special situation businesses. - Up to $250+ million hold size per transaction. Potential for follow-on capital.

The Comvest Investment Partners VI, L.P. fund (CIP VI) is a private equity that has closed with total capital commitments of $881 million. The fund targets control investments in market-leading middle-market companies throughout North America, with a focus on industries such as consumer, healthcare services, infrastructure and field services, and professional and managed services. The fund seeks to deploy up to $150 million of equity per investment and supports founder and family transitions, leveraged recapitalizations, corporate divestitures, buyouts, complex situations, and public-to-private transactions. The fund received commitments from a diverse global investor group that includes foundations, insurance companies, pension funds, asset managers, consultants, and family offices. Comvest Partners, the firm managing the fund, has nearly 25 years of experience in delivering results for investors and a proven investment team. Comvest's private equity strategy integrates specialized investment, industry, and operational expertise to help company founders and management teams scale their businesses, heighten operational performance, and drive value creation to realize their full potential. The firm has a collaborative approach and significant transaction experience as an active investor.

Crestline Direct Lending Fund IV (CDLIV) is the fourth installment of Crestline Investors’ flagship direct lending strategy, which recently closed with $3.5 billion in investable capital, including anticipated leverage. The fund focuses on providing tailored financing solutions to sponsor and non-sponsor backed companies across North America, particularly within the lower and core segments of the middle market. Since its inception in 2014, Crestline's direct lending strategy has completed over 150 transactions, deploying more than $5.9 billion in capital. CDLIV has already executed 46 transactions across a diverse array of borrower profiles, industries, and sponsors, demonstrating the firm's commitment to flexible, scalable capital solutions. The fund attracted a globally diversified investor base, including public and corporate pension plans, sovereign wealth funds, asset managers, registered investment advisors, and other financial institutions from North America, Europe, and Asia. This broad support underscores Crestline's reputation as a trusted steward of capital and its ability to deliver returns and capital preservation through various credit cycles.

Dent&Co, a fund launched by Miura Partners, has raised over €200 million from international institutional investors. The fund is specifically targeted to back Proclinic Group, a leading dental distribution company in Europe, in its next phase of growth and consolidation through acquisitions. Proclinic Group, headquartered in Zaragoza, Spain, is a leading pan-European integrated provider of solutions for the dental sector with a strong omnichannel presence in key European markets. The company offers a broad product portfolio of dental consumables and equipment, as well as value-added services such as after-sales training, technical support, and digitalization. Dent&Co aims to further develop the growth plan of Proclinic Group by reinforcing the commercial strategy, expanding products and services, integrating new acquisitions, and exploring new M&A opportunities in other European countries. The fund's investment in Proclinic Group has already driven important value-generating initiatives, including management reinforcement, strategic acquisitions in key geographies and new business lines, commitment to digitalization, investment in leading logistics platforms, and sustainability initiatives. With annual sales reaching €256 million in 2023 and an annual growth of 29% since 2020, Proclinic Group represents a well-invested and differentiated platform with a proven ability to execute growth. Overall, Dent&Co targets investments in small and medium-sized family-owned and entrepreneurial companies within the dental sector in Europe, with a clear focus on sustainability."

ECP Growth, formerly known as Emil Capital Partners, is a growth-stage investment firm dedicated to partnering with entrepreneurial businesses that create innovative products, solutions, and technologies within the consumer value chain. Established in 2011 in collaboration with the Tengelmann Group, a 150-year-old family-owned holding company, ECP Growth leverages deep industry expertise to support companies in navigating complex growth challenges. With the recent close of its $100 million Fund IV, ECP Growth aims to invest in high-potential companies situated at the intersection of significant market transformations and evolving consumer needs. The firm adopts a thematic investment approach, focusing on sectors that enhance human mobility across life stages, deliver personalized health and wellness experiences, and optimize resource efficiency in daily living. ECP Growth typically partners with companies generating over $10 million in revenue, offering investment sizes ranging from $5 million to $20 million. The firm emphasizes businesses that demonstrate a clear path to profitability within 18 months, ensuring both immediate growth potential and sustainable long-term value.

EQT XI is a flagship private equity fund targeting a €23 billion raise, designed with strategy continuity from its predecessor, EQT X. Its fund cycle syncs precisely with EQT X—launching when the older fund is ~80–90 percent invested. The capital will be deployed across mid- to large-cap sectors, leveraging EQT’s global private equity capabilities. Fund investment strategy largely mirrors that of EQT X, focusing on resilient sectors in Europe, North America, and Asia-Pacific. With deep sector expertise in healthcare, technology, services, and infrastructure, EQT XI aims to build on past successes and value creation methodologies honed over multiple generations of flagship funds. The fee structure is aligned seamlessly with investors' interests: management fees commence upon the first investment by EQT XI or when EQT X’s commitment period ends, whichever comes first. After that point, EQT X’s fee basis shifts to net‑invested capital, ensuring clean fund transitions and consistent alignment between fund manager and LPs.

The Eighth Cinven Fund (Fund 8) is a buyot fund managed by Cinven. It has raised $14.5 billion and is nearly 30% larger than its predecessor fund, Fund 7. The fund has benefitted from a strong re-up rate from longstanding Limited Partners and welcomed new investors to its global Limited Partner base. The success of the fundraise is attributed to the long-term track record, depth and experience of the team, and the consistency of its strategy in building long-term, sustainable businesses with global growth opportunities. Cinven usually investors in the following sectors: Business Services, Consumer, TMT, Healthcare, Financial Services and Industrial. The strategy for Fund 8 builds on the approach successfully used in previous funds, investing in control positions in growth-oriented, market-leading, cash-generative companies. Cinven seeks to accelerate growth through active management and deliver break-out returns. The fund seeks to invest across sectors and geographies, particularly during periods of volatility, to identify attractive opportunities. Cinven seeks to build long-term, sustainable businesses that will grow, provide employment, and generate economic benefit in an environmentally and socially responsible manner. With a proven track record of investing successfully through economic cycles, the Cinven Funds have completed investments in more than 150 portfolio companies across Europe and in North America and realized or listed more than 115 investments, returning proceeds of approximately €47 billion to the Cinven Funds. Founded as the private investment arm of the British Coal pension scheme in 1977, Cinven became independent in 1995 and has raised more than €50 billion in aggregate to date through various funds."

Equitage Ventures Fund I is a $47.3 million early-stage venture capital fund launched in April 2025 by Denver-based Equitage Ventures. The fund focuses on investing in technology and technology-enabled services that address the physical, mental, spiritual, and social needs of older adults. Led by a team of seasoned investors and operators—Russell Hirsch (co-founder of Generator Ventures), Adam Kaplan (CEO of Solera Senior Living), and Daniel Kaplan (AgeTech investor)—the fund aims to reshape how senior care is delivered through innovation and scale. Equitage partners with senior living and skilled nursing operators, home health and hospice agencies, healthcare tech firms, and consumer brands. These limited partners not only provide capital, but also strategic input, distribution channels, and hands-on support to accelerate portfolio growth. The fund focuses on critical areas of need and opportunity, including compliance infrastructure, documentation automation, passive monitoring, dementia and behavioral health, oral health, care navigation, and family caregiving support. Equitage takes a founder-friendly, collaborative approach, often investing between $250,000 and $2.5 million per company, and positioning itself as a long-term partner offering more than just capital. The fund seeks to create meaningful change in senior care by supporting scalable, impactful innovations across the U.S.

Escalate Capital V is a growth capital fund by Escalate Capital Partners. The fund is located in Austin, Texas and prefers investing in United Sates. The fund targets technology, software, services, and healthcare sectors. The fund invests in rapidly growing later-stage companies with minimum revenues of $20 million and minimum EBITDA of $3 million. Sectors of interest include technology, software, services, and healthcare across the United States. As of May 2025, the fund has already closed on two investments representing $35 million of Fund V’s committed capital. Since its founding in 2005, Escalate has invested over $1.3 billion of capital in 140 growth equity-backed companies.

Eurazeo PME IV is a €1.1 billion private equity buyout fund managed by Eurazeo, focusing on small to mid-sized French companies. Launched in 2022, it surpassed its predecessor by 50%, reflecting strong investor confidence in Eurazeo’s strategy. The fund targets enterprises valued between €50 million and €500 million, with investments ranging from €20 million to €100 million. The fund's strategy centers on supporting leading French SMEs in their international growth and transformation. By providing capital and strategic guidance, Eurazeo PME IV aims to help these companies expand their global footprint and enhance operational capabilities. The fund leverages Eurazeo’s extensive network and expertise to drive value creation. Eurazeo PME IV has attracted a diverse group of investors, including institutional investors, sovereign funds, insurance companies, and family offices from France, Europe, and Asia. This broad investor base underscores the fund's strong market appeal and Eurazeo's reputation in the private equity landscape.

The Evergreen Park Investment Fund is a co-investment private equity vehicle managed by Fisher Lynch Capital, a boutique firm specializing in collaborative investments. Launched in 2021, the fund was initially capitalized with $2 billion from the Washington State Investment Board (WSIB), its sole limited partner. Subsequent commitments of $1 billion in 2023 and $800 million in 2024 have brought total assets under management to $3.8 billion. The fund's strategy focuses on co-investing alongside existing private equity managers in which WSIB already holds positions. This approach allows for enhanced alignment with WSIB's broader investment portfolio and leverages established relationships to access high-quality deal flow. The fund targets buyout and growth equity opportunities, aiming to capitalize on the expertise of its partner managers. Fisher Lynch Capital, headquartered in San Mateo, California, brings a disciplined investment process and a track record of successful co-investments. The firm evaluates deals across various industries and geographies, seeking opportunities that offer strong potential for value creation. The Evergreen Park Investment Fund represents a significant commitment to this collaborative investment model, aligning the interests of WSIB and Fisher Lynch Capital in pursuing long-term growth.

Five Arrows Secondary Opportunities VI (FASO VI) is Five Arrows' sixth secondaries fund with €2 billion size. This achievement surpasses its original target of €1.5 billion and doubles the size of its predecessor, FASO V. The fund focuses on mid-market GP-led secondary transactions, emphasizing companies in the healthcare, business services, software, and IT sectors across Europe and North America. FASO VI is part of the Five Arrows Multi-Strategies platform (FAMS), which manages over €28 billion in assets across various strategies, including corporate private equity, primary and secondary fund investing, co-investments, and senior and junior credit. The fund received strong support from a globally diversified group of investors, including pension funds, insurance companies, corporations, family offices, and entrepreneurs. Notably, Rothschild & Co Group, along with its staff and investment team, made a substantial commitment to the vehicle. The fund's investment strategy is designed to capitalize on the growing GP-led secondaries market, which expanded to over $71 billion in 2024 from $29 billion in 2019. With a team that has worked together for over two decades, Five Arrows leverages its extensive experience to identify and execute transactions that offer attractive risk-adjusted returns. FASO VI aims to provide liquidity solutions to general partners and limited partners, facilitating the continuation and growth of high-quality assets.

The fund is the fourth flagship vehicle from GHO Capital, leveraging its deep specialization in healthcare to back companies delivering better, faster and more accessible care. With its final close at over €2.5 billion, the vehicle is positioned to scale high‑growth businesses across services, medtech, diagnostics and health‑tech platforms. GHO Capital IV focuses on companies where strong management, operational improvement and international expansion can unlock significant value. The fund partners with leadership teams in niche but growing healthcare subsectors and applies the firm’s sector insight, global network and operational resources to drive transformation. The strategy targets enterprises that serve pharmaceutical, biotechnology and medical device customers — such as CDMOs, contract services, outsourcing platforms, diagnostics manufacturers and digital health enablers — where structural tailwinds and under‑penetrated markets offer runway for growth. Geographically, the fund emphasises Europe and North America but retains flexibility to leverage cross‑border dynamics, enabling portfolio companies to scale internationally. Through disciplined buy‑outs, add‑on consolidation and operational acceleration, GHO Capital IV aims to d

GTCR Capital Solutions Fund is the inaugural fund under GTCR's new capital solutions strategy, launched in 2024. The fund focuses on providing minority structured equity and debt investments to mid-market companies, offering flexible financing solutions tailored to each company's specific needs. This strategy formalizes GTCR's approach to minority investments, allowing the firm to offer bespoke capital structures that can include convertible debt, preferred equity, and other hybrid instruments. The fund targets companies across various sectors, including business services, technology, media and telecommunications (TMT), financial services, and healthcare. With a target size of $1.5 billion, the fund has attracted commitments from institutional investors such as the Washington State Investment Board, which approved a $100 million investment in November 2024. The fund is domiciled in Delaware and managed from GTCR's headquarters in Chicago.

Gemspring Growth Solutions II is the second non‑control / growth capital fund under the “Growth Solutions” banner, positioned to back middle‑market companies with scalable growth trajectories. The fund provides flexible, minority or structured equity investments as a partner to management teams, rather than seeking full control. Its purpose is to leverage Gemspring’s operational capabilities, strategic oversight, and networks to accelerate growth, margin expansion, and value creation in portfolio companies. GGS II is oriented toward businesses that already exhibit strong fundamentals and growth potential, but require additional capital, strategic resources, and operational insight to scale more aggressively. By adopting a flexible capital approach, the fund can structure its investments in the form of growth equity, preferred equity, recapitalizations, or structured instruments that align incentives with existing shareholders. Over time, the fund may also support add‑on acquisitions or strategic inorganic growth to enhance scale and market leadership. Gemspring is likely to target sectors consistent with its existing “Growth Solutions” and broader firm strategy: software, tech‑enabled services, industrial services, business services, specialty manufacturing, healthcare services, and adjacent segments. The fund can capitalize on opportunities that lie in both technology‑driven growth areas and more traditional industrial or services domains, especially where transformation or scaling is needed. Given its predecessor track record and the firm’s reputation, GGS II may attract high‑quality sponsors, founders, or management teams looking for a growth partner rather than a full take‑private transaction. Its non‑control posture allows for more flexible deal structures, enabling participation in opportunities that are less conducive to traditional buyouts, and broadening the investible universe for Gemspring.

Goldman Sachs Alternatives launched the open-ended European Private Credit Strategy (GSEC) in early 2024, targeting resilient European mid-sized businesses through senior secured lending. As of mid-2025, the fund has raised over €6 billion in assets under management, becoming one of the largest open-ended private credit strategies in Europe. The fund invests primarily in directly originated, senior secured loans to high-quality, sponsor-backed companies. These companies are typically cash-flow generative and operate in sectors with low cyclicality. GSEC’s flexible evergreen structure allows it to serve institutional and wealth investors seeking access to private credit with periodic liquidity. Over 75% of GSEC’s portfolio is allocated to first-lien senior loans in recession-resilient sectors such as healthcare, software, and essential business services. Goldman Sachs employs a disciplined underwriting process and conservative leverage metrics to ensure capital preservation and income stability. The strategy benefits from Goldman Sachs’ scale, sourcing network, and due diligence capabilities. GSEC integrates ESG analysis, sectoral diversification, and active portfolio monitoring to deliver long-term, risk-adjusted returns for its global investor base.

Great Hill Equity Partners IX, L.P. represents the ninth iteration of the firm’s flagship growth buyout fund series. Closed in September 2025, this fund reached $7 billion in committed capital—well above its $5 billion target—and achieved its hard cap just five months after its formal launch, underscoring strong investor demand and confidence in the firm’s strategy. Continuing Great Hill’s well-established middle‑market growth buyout strategy, Fund IX targets rapidly scaling companies across the software, financial services, healthcare, consumer, and business services sectors. This enduring focus reflects the firm’s track record of seeking disruptive, high‑growth opportunities where it can provide operational and strategic value. The fund attracted a wide‑ranging investor base from North America, Europe, Asia, the Middle East, South America, and Australia. Its investors include public and private pension funds, sovereign wealth funds, endowments and foundations, insurance companies, healthcare systems, institutional fund managers, family offices, and high‑net‑worth individuals—many of whom have previously backed Great Hill's prior funds. In tandem with the launch of Fund IX, Great Hill made key leadership adjustments: Managing Directors Chris Busby, Nick Cayer, Rafael Cofiño, and Drew Loucks joined the Executive Committee, complementing existing members Chris Gaffney, Mark Taber, and Matt Vettel. Michael Kumin transitioned to Senior Advisor, continuing to manage his existing portfolio responsibilities. Latham & Watkins LLP served as legal counsel for the fund’s formation.

Gyrus Capital, a Geneva-based private equity firm specializing in healthcare and sustainability sectors, has successfully closed a €700 million single-asset continuation fund dedicated to Essential Pharma. Essential Pharma is an international specialty pharmaceutical group focused on providing access to low-volume, clinically differentiated, niche pharmaceutical products across key therapeutic areas. The continuation fund was led by AlpInvest Partners, a subsidiary of Carlyle Global Investment Solutions, with significant participation from StepStone Group and other new and existing investors. Both Gyrus Capital and Essential Pharma's management team have made meaningful reinvestments in the fund. This transaction provides Essential Pharma with substantial additional capital to expand its diversified portfolio of established and rare disease medicines through acquisitions and development strategies. The company operates globally in more than 70 countries, supplying over 300 products across multiple therapeutic areas.

Hellman & Friedman Capital Partners XI is a private equity buyout fund managed by Hellman & Friedman that focuses on investing in a range of sectors, including technology, financial services, healthcare, retail and consumer products. Geographically, the fund targets companies primarily in North America and Europe, with a focus on established businesses with strong growth potential and proven track records. The fund is located in San Francisco, California. In terms of financial targets, the fund typically looks for companies with annual revenues of $500 million or more, and EBITDA of at least $100 million, indicating a preference for larger, more established businesses. The fund will invest between $400 million and $4 billion in mid to large caps. Overall, Hellman & Friedman Capital Partners XI seeks to invest in companies with strong management teams, competitive market positions, and opportunities for operational improvement and growth.

The $750 million private equity multi-asset continuation fund announced by Hildred Capital is focused on healthcare and specializes in partnering with middle-market companies. The fund was structured to align the interests of the general partnership and limited partners, with the co-founders rolling over 100% of their economic interests into the continuation fund. Limited partners had the option to roll all, sell all, or sell a portion of their interests and roll a portion into the continuation fund. This fund aims to provide additional committed capital for companies to execute organic growth initiatives, pursue strategic acquisitions, and continue to drive operating leverage. It has generated significant liquidity and attractive returns for selling limited partners while also providing new investors with the opportunity to participate over time in the appreciation of strong and growing companies.

IK Small Cap IV closed on 24 July 2025 with €2.0 billion in total commitments, reaching its hard cap and concluding the fundraise within just six months. The strong investor response underscores IK Partners’ continued success in the small-cap segment and highlights market confidence in the firm's ability to identify and scale lower mid-market businesses across Europe. The fund includes a dedicated €600 million Development Capital pool focused on smaller companies with enterprise values between €20 million and €80 million. The core Small Cap IV strategy targets companies with enterprise values ranging from €80 million to €200 million. This dual-track structure allows IK to address a broader range of opportunities and tailor capital solutions across the small-cap spectrum. IK Small Cap IV received broad support from institutional investors worldwide. Approximately 71% of the capital came from EMEA-based investors, 18% from North America, and 11% from Asia. Notably, around 80% of the capital commitments were from existing investors across the IK platform, demonstrating strong loyalty and ongoing trust in the firm’s investment capabilities. Specific LP names were not disclosed, although the Minnesota State Board of Investment was identified in public records.

INVL Baltic Sea Growth Fund, managed by INVL Asset Management, is a closed-end private equity fund launched in June 2018 with committed capital of €164.7 million. The fund invests in late-stage growth SMEs and small to mid-cap companies, acquiring either controlling or significant minority stakes. Typical equity investments range from €5 million to €25 million, with capacity for larger deals via co-investments. Target companies are generally valued between €10 million and €100 million. The fund focuses on businesses with strong potential to become industry leaders in their respective sectors. Core geographies include the Baltic States and Poland, while investment scope extends across the broader European Union. INVL Baltic Sea Growth Fund specializes in complex transactions, providing customized capital solutions for companies undergoing structural, strategic, or ownership transitions. It supports growth through a combination of organic expansion, acquisitions, and active value creation initiatives. Taking an active ownership approach, the fund works closely with management teams to align long-term goals and drive transformation. It typically invests by acquiring stakes from existing shareholders and providing growth capital. With an ESG-integrated investment model and a hands-on strategy, INVL Baltic Sea Growth Fund helps its portfolio companies scale operations, increase efficiency, and execute cross-border expansion strategies.

KKR North America Fund XIV is the fourteenth flagship buyout fund managed by KKR & Co. Inc., a leading global investment firm. Launched in June 2024, the fund aims to raise $20 billion, slightly exceeding its predecessor, Fund XIII, which closed at $19 billion in March 2022. Fund XIV continues KKR's strategy of investing in large-scale buyouts across various sectors, leveraging the firm's extensive experience and global network.The fund focuses on investments in North America, particularly the United States, Canada, and Mexico, with an additional emphasis on opportunities in Latin America. KKR seeks to deploy capital steadily, targeting an annual deployment rate of 20% to 25% of the fund's total capital. The fund aims for a net internal rate of return (IRR) in the high-teens, reflecting KKR's commitment to delivering strong returns to its investors. Fund XIV has attracted commitments from various institutional investors, including a $365 million commitment from the Oregon State Treasury and a $70 million commitment from Fubon Life Insurance. As of April 2025, KKR has raised approximately 70% of the fund's target, securing $14 billion in its first close.

Kamet Founders Fund 1 is a $70 million 2022 vintage buyout fund managed by Kamet Capital Partners. The fund is located Singapore. The fund closed below its $100 million original target set in early 2022 when it started fundraising for the vehicle. Kamet Capital employs innovative techniques and a flexible approach to curate custom strategies for families: 1. It focuses on the growth markets of US, China and Southeast Asia.. 2. Investing in Growth and Innovation within 3 Key themes of Technology, Consumer, and Healthcare. The bulk of the commitments in the first close (US$50 million) came from Kamet Capital’s existing stable of family office clients. About a third of the funds were from two new family offices based in Singapore, and ultra high net worth individuals. The first investment of the fund was into a Chinese semiconductor startup’s Series A round. The company designs and sells data processing units, used in data centres. The fund also invested in Pax8, as part of the cloud ecommerce marketplace’s recent $185 million fundraising led by Softbank Vision Fund 2.

L Catterton India Fund I marks the firm’s first India-dedicated investment vehicle focused exclusively on the consumer sector. Backed by LVMH and co-led by Sanjiv Mehta (former CEO of Hindustan Unilever), the fund aims to capitalize on India’s fast-growing consumption trends. Launched in 2024, the fund operates as a determinate close-ended trust registered under SEBI's Category II AIF regime, reflecting strong compliance and governance standards. With a fundraising target of $600 million, the fund achieved a first close of $200 million in September 2025. Key anchor commitments include International Finance Corporation (IFC) with $30 million, and clients of Kotak Private. The fund also has a green-shoe option of an additional $200 million, potentially increasing the total fund size to $800 million. The fund will deploy capital across 7 to 9 mid-stage companies, with investment tickets ranging from $25 million to $150 million. L Catterton India Fund I will focus on high-growth consumer sub-sectors such as food & beverage, consumer services (including healthcare), retail & restaurants, and consumer brands. Its strategy aligns with India’s expanding middle class and rising disposable incomes. L Catterton India Fund I leverages the global private equity expertise of L Catterton and the local leadership of Sanjiv Mehta. Backed by institutional LPs like IFC and supported by distribution through Kotak Private, the fund combines capital with operational value-add to help Indian consumer companies scale both locally and internationally. The fund’s value proposition is centered on growth acceleration and brand building.

Lakestar Early IV is an early-stage venture capital fund managed by Lakestar. The fund is domiciled the United Kingdom. The fund will focus their investments across geographies, with a focus on Europe in sectors such as AI, digitalisation, deep tech, healthcare, and fintech. The funds are aligned with Lakestar’s commitment to forge a stronger future for Europe by nurturing the region’s innovation and tech ecosystem through the funding of business models which support economic growth and social prosperity. The fund closed in April 2024 together Lakestar Growth II with $600 million.

Lakestar Growth II is a growth venture capital fund managed by Lakestar. The fund is domiciled the United Kingdom. The fund will focus their investments across geographies, with a focus on Europe in sectors such as AI, digitalisation, deep tech, healthcare, and fintech. The funds are aligned with Lakestar’s commitment to forge a stronger future for Europe by nurturing the region’s innovation and tech ecosystem through the funding of business models which support economic growth and social prosperity. The fund closed in April 2024 together Lakestar Early IV II with $600 million.

The Libra Hybrid Capital Fund is a private credit vehicle launched by Granite Asia, a Singapore-based multi-asset investment platform. The fund has secured over US$250 million in anchor commitments from leading Asian sovereign wealth funds, general partners, and a network of founders and entrepreneurs. With a target size of US$500 million, the fund aims to provide non-dilutive capital to mid-market companies across the Asia-Pacific region. Libra focuses on offering secured loans with a defensive risk profile, targeting established businesses that are profitable or have positive cash flow. These companies span various sectors, including those undergoing digital transformation or pursuing growth through acquisitions. The fund leverages Granite Asia's technology ecosystem and operational expertise to deliver stable cash yields and enhanced returns. Managed by partners Ming Eng and Roger Zhang, the fund is part of Granite Asia's broader strategy to support a diverse range of businesses that form the backbone of Asia's economy. By providing flexible, non-dilutive financing solutions, Libra aims to bridge funding gaps for companies scaling within and across the region.

Linden Capital Partners, a Chicago-based private equity firm specializing in healthcare, has successfully closed its sixth buyout fund, Linden Capital Partners VI, at $5.4 billion. This marks a major milestone, surpassing its $4.5 billion target and initial $5.0 billion hard cap. The fund secured $5.2 billion in LP commitments from investors in more than 20 countries, along with a $200 million general partner commitment. Fund VI will continue Linden’s long-standing strategy of investing in middle-market healthcare companies, with a focus on services, products, and distribution segments. The firm brings a disciplined approach to value creation, combining deep operational expertise, tailored growth strategies, and a unique human capital model to support long-term success. The fund's investor base includes major institutional investors such as the New York State Teachers’ Retirement System, Texas County & District Retirement System, Louisiana State Employees’ Retirement System, Sacramento County Employees’ Retirement System, and Fairfax County Educational Employees’ Supplementary Retirement System. The oversubscribed fund closed in under nine months, highlighting strong investor demand and Linden’s leadership in healthcare investing.

Main Capital Partners is a private equity buyout fund based in The Hague (Netherlands) that invests in the software sector. Main Capital VIII closed at its hard caps of €1.9 billion in just 6 months’ time, well past their initial target size. The fund was substantially oversubscribed. Main Flagship invests in mature and growing software businesses with equity tickets over from €20 million to €150 million, focusing on fueling growth through strategic acquisitions. The fund had a significant re-up rate of 115% from existing limited partners (LPs), demonstrating strong support from the LP base. A notable aspect of the fundraising is the increasingly global institutional LP base, with close to 25% of commitments coming from US investors. Its portfolio companies are supported by in-house Market Intelligence & Performance Excellence teams, providing access to proprietary data & research and best practices on go-to-market strategies, technology, finance, and M&A. Main is deeply connected with the local software ecosystems in its core markets, including Benelux, DACH, Nordics, and the US. Main’s key goal is to build larger international software groups, based on organic growth and acquisitions, in approximately 10 defined product-markets such as Healthtech, Govtech, HRtech, and Cybersecurity. Main Capital Partners did not use a placement agent for the fundraising, and Loyens & Loeff acted as legal counsel. The successful closing of the funds reinforces Main’s position as a European leader in software buyouts and signifies the continued trust and support it has received from its LPs. Over the years, Main has realized close to 30 exits with a weighted average return over 4x and a loss rate well below 0.5%, demonstrating the firm’s strong investment performance and specialized focus on Enterprise Software investing."

Main Foundation II is a private equity fund based in The Hague (Netherlands) investing in software growth companies. Main Foundation II closed at its hard caps of €500 million in just 6 months’ time, well past their initial target size. The fund was substantially oversubscribed. Main Foundation invests in high-growth software businesses with equity tickets below €20 million, focusing on organic growth. The fund invests in companies with headquarters in Benelux, DACH and the Nordics. The fund had a re-up rate of 115%. Besides re-ups from existing investors, Main attracted many new investors, amongst which were reputable institutional investors such as APG (on behalf of its client ABP), Tecta Invest and Texas County and District Retirement System. Existing investors, such as Hamilton Lane, increased their commitments.

The Mastercard Foundation Africa Growth Fund is a $200 million Fund-of-Funds initiative that supports African-owned and African-led investment vehicles. These vehicles finance early-stage and growth-oriented small and medium-sized enterprises (SMEs) with the aim of fostering inclusive economic development across sub-Saharan Africa. The Fund is deeply focused on enabling dignified and fulfilling work opportunities for young people, especially young women. It accomplishes this by de-risking and strengthening impact investment vehicles that are committed to gender equity and social inclusion. Since its launch in 2022, the Fund has backed 18 investment vehicles operating in 12 African countries, facilitating financing for 49 SMEs and creating more than 2,500 full-time jobs—over 1,100 of which are held by women. Through this structure, the Fund not only boosts access to capital for underrepresented entrepreneurs but also builds the long-term capacity of Africa’s investment ecosystem.

Mayfield Select III, also known as Mayfield Spring, is a $375 million venture capital fund launched by Mayfield in May 2023. This fund is designed to invest in Series B rounds, focusing on both follow-on investments in breakout companies from Mayfield's existing portfolio and new opportunities outside of it. The fund aims to support companies that have demonstrated early product-market fit and are poised for significant growth. The fund targets sectors at the intersection of technology and biology, including human-centered AI, the data economy, developer-first technologies, semiconductors, cybersecurity, deeptech, Web3, and human and planetary health. Mayfield's investment philosophy emphasizes a people-first approach, partnering closely with founders to build enduring companies. With Mayfield Select III, the firm continues its tradition of backing visionary entrepreneurs during pivotal growth stages, providing not just capital but also strategic guidance and support. The fund reflects Mayfield's commitment to fostering innovation and addressing some of the most pressing challenges and opportunities in today's rapidly evolving technological landscape.

Mediterrania Capital IV Mid Cap (MC IV) is a private equity fund managed by Mediterrania Capital Partners, focusing on growth investments in mid-cap companies across North Africa and Francophone Sub-Saharan Africa. With a target fund size of €350 million, MC IV aims to support businesses with strong growth potential and established market positions. The fund seeks to invest in sectors crucial for the region's development, including healthcare, education, financial services, consumer goods, and manufacturing. By providing both capital and strategic support, MC IV assists companies in scaling operations, enhancing governance, and expanding into new markets. MC IV is committed to responsible investing, integrating environmental, social, and governance (ESG) considerations into its investment process. The fund also emphasizes gender diversity, aligning with the 2X Challenge by aiming for a significant portion of its portfolio to meet gender inclusion criteria.

Menlo Ventures XVII is an early-stage venture capital fund managed by Menlo Ventures, legally domiciled in Delaware and headquartered in Menlo Park, California. Officially formed in August 2025, the fund aims to back early-growth technology startups with long-term disruptive potential. The fund is targeting investments in 30 to 40 companies, typically writing checks between $8 million and $15 million. This capital deployment strategy aligns with Menlo Ventures' mission to support startups from seed through early expansion, providing not just capital, but also strategic and operational guidance. The fund’s general partners include prominent investors such as Venky Ganesan, Shawn Carolan, and Matt Murphy, who are key figures in the Menlo Ventures leadership team. Their combined track record includes successful investments in high-profile companies across multiple sectors. Menlo Ventures XVII is part of the firm’s broader strategy to expand its footprint in areas like artificial intelligence, enterprise software, healthcare, and fintech. The fund continues Menlo’s legacy of identifying and supporting companies positioned to lead their industries through innovation.

MPEP VI is a €350 million fund-of-funds that maintains MPEP's "pure play" strategy, investing exclusively in primary buyout funds within the lower mid-market. The fund is structured into two separate vehicles, allowing institutional investors to customize their geographic exposure between Europe and North America. Classified as an Article 8 product under the Sustainable Finance Disclosure Regulation (SFDR), MPEP VI underscores a commitment to integrating sustainability considerations into its investment process. The fund aims to invest in 10 to 12 buyout funds per region, selecting managers based on consistent outperformance, sourcing advantages, and alignment of interests. Since its inception in 2011, MPEP has backed over 100 buyout funds, achieving a gross multiple on invested capital (MOIC) of 3.6x across 121 realized exits. The firm's investor base includes pension funds, banks, insurers, family offices, and foundations both in Germany and internationally.

Mérieux Innovation 2 (MI2) is the second-generation venture capital fund managed by Mérieux Equity Partners, focused on advancing innovation in the healthcare sector. Building on the success of its predecessor, MI2 is designed to support early-stage companies with high-impact solutions across diagnostics, medical devices, and pharmaceutical services. The fund targets platform-based business models with validated proof of concept, offering scalability and long-term growth potential. MI2 combines capital investment with strategic guidance and access to a robust healthcare ecosystem, helping portfolio companies accelerate development and go-to-market strategies. MI2 has received the prestigious Tibi label, highlighting its commitment to driving technological innovation within France and the broader European healthcare landscape. It aims to generate strong returns while contributing meaningfully to patient care and clinical outcomes. The fund’s first investment is a €6 million commitment to DeepUll, a Spanish diagnostics company developing rapid sepsis detection technology. This aligns with MI2’s goal of supporting transformative platforms that address critical medical needs.

New Mountain Partners VII is a buyout fund managed by New Mountain Capital and located in New York. The fund will acquire controlling stakes in companies valued between $100 million and $1 billion, typically investing between $100 million and $500 million per transaction​. New Mountain Capital targets sectors characterized by sustainable and noncyclical growth, which they refer to as "defensive growth industries." These include life sciences, advanced materials, healthcare technologies, infrastructure services, and digital transformation services, among others. As of APril 2024, the fund has raised US$12.4 billion, above its target of US$12 billion. The fund expects to do around 20 investments.

NewSpring Health Capital IV is a growth equity fund that targets high-growth, lower-middle market companies focused on technology-enabled healthcare services and niche clinical providers. The fund aims to invest in companies that influence healthcare by using technology and human capital in novel ways, with a focus on easing access to care, improving outcomes, and increasing efficiency while lowering costs. With a focus on proprietary deal flow, the fund has made investments in specialized pharmaceutical distribution services, sleep disorders management, cardiovascular staffing, dysphagia diagnostics, business process outsourcing services for behavioral health programs, and healthcare disclosure management technology and services. The fund's target investments are companies that evolve and shape high-impact sectors in healthcare. NewSpring Health Capital IV seeks to invest from $10 to $25 million in lower-middle market companies that have between $10 to $100 million in revenue at the time of investment. The fund has raised over $180 million and received strong support from existing and new investors, including a diverse group of strategics, financial institutions, and family offices. The fund is led by a team with extensive expertise in different segments of healthcare, including a team of advisory partners with deep industry experience. With a deep and growing deal pipeline of innovative healthcare companies, the fund will capitalize on the escalating opportunities and growing momentum within this segment of the market.

North Haven Capital Partners VIII (NHCP VIII), managed by Morgan Stanley Capital Partners, is a North American control buyout fund targeting lower middle‑market companies with strong EBITDA or free cash flow profiles. With its final close dated June 23, 2025, the fund amassed approximately US $3.2 billion in commitments, positioning it as a significant vehicle for growth‑oriented investments. The fund focuses on leadership‑driven businesses poised for strategic transformation across information technology, business services, healthcare, industrials, manufacturing, distribution, and logistics sectors. NHCP VIII pursues control stakes in founder‑owned or owner‑operated firms, often executing transactions such as recaps, spin‑outs, or succession‑related transitions. A key criterion is companies with at least US $1 million in EBITDA or free cash flow, underscoring the fund’s emphasis on operational strength. Leveraging the deep operational and sector expertise of Morgan Stanley’s private equity team, NHCP VIII aims to partner closely with management teams to enhance performance and scale businesses. Investments are concentrated in North America, with vehicle domiciles in Delaware and Luxembourg, providing flexibility and access to both domestic and international limited partners.

Northlane Capital Partners III is the third flagship fund launched by Northlane, reflecting the firm’s continued focus on middle‑market investments in the healthcare and business services sectors. The fund closed at $750 million, exceeding its original target of $550 million and significantly outpacing prior fund sizes. NCP III seeks to partner with founder‑ or management‑led companies that are niche market leaders, with defensible positioning, disciplined cost structures, and opportunities for operational scaling through technology, M&A, and strategic expansion. The fund builds on Northlane’s track record of executing in specialized subverticals where deep domain knowledge and active value creation can yield outsized returns. In deploying capital, NCP III is expected to emphasize partnerships where Northlane can bring not just capital, but operational support: structuring add‑on acquisitions, leadership upgrades, service line expansion, and geographic scale. Given the firm’s past execution and sector focus, deep diligence, alignment incentives, and post‑acquisition oversight will be central to its approach. Though the fund is new and still in deployment, NCP III leverages Northlane’s prior investments and relationships across healthcare and business services in U.S. lower‑middle to middle market companies. The fund’s ambition is to back durable, scalable growth trajectories in sectors resilient to economic cyclicality.

Oak HC/FT Partners VI is a venture capital fund managed by Oak HC/FT, focused on investing in high‑growth companies at the intersection of healthcare information services and financial services technology. Based in Stamford, Connecticut, the fund benefits from the firm’s deep domain expertise and hands‑on partnership approach. The fund typically participates in early and growth‑stage rounds, deploying investment tickets ranging from $15 million to $35 million in earlier‑stage opportunities and $5 million to $50 million in growth‑stage companies. Oak HC/FT seeks to back businesses that are driving structural transformation in healthcare and fintech through innovative, scalable models. With a strategy centered on deep collaboration, Oak HC/FT provides more than capital—they bring board‑level engagement, go‑to‑market support, and access to an extensive network of industry leaders. The fund is actively deploying capital in U.S.‑based companies committed to reshaping financial and healthcare ecosystems.

PAI Mid‑Market Fund II is a European buy‑out fund managed by PAI Partners, domiciled in Luxembourg with management operations led from Paris. The fund builds on PAI’s inaugural mid‑market platform and aims to support growth and consolidation in medium‑sized companies across Europe. It focuses on businesses in sectors including business services, consumer & food, industrials, and healthcare, leveraging PAI’s operational expertise in these areas. Target geography includes major European markets such as France, Spain, Italy and Germany. The fund seeks enterprise value targets broadly in the range of €100‑300 million per company, with equity tickets from €70 million and above, depending on deal size and opportunity. It applies a buy‑and‑build or transformational strategy, working closely with management teams to scale operations and possibly expand cross‑border. As a successor fund, MMF II is likely to follow similar fund size, investment pacing, and ESG and operational value‑creation frameworks as the original MMF, while adapting to current market conditions and valuation landscapes.

PCP SEE Fund II is a private equity fund focused on the Southeast Europe (SEE) region, launched by Provectus Capital Partners with a first close of €162.5 million and a final target of up to €250 million. The fund builds on the momentum of its predecessor, PCP Fund I, which closed in 2020 with €95 million in commitments. With Fund II, Provectus is expanding its sectoral focus beyond healthcare into other fragmented, high-growth sectors that are ripe for regional consolidation. The fund is designed to support companies with the potential to become regional champions, leveraging operational improvements and strategic acquisitions. The investment strategy centers on Buy & Build, targeting equity tickets of €15–25 million per platform company, typically deployed in stages and enhanced through additional debt and co-investments. The firm is also strengthening its local sourcing and execution capacity by opening offices in Bucharest and Sofia, enhancing its reach across Romania and Bulgaria. PCP SEE Fund II aims to scale companies through active ownership, add-on acquisitions, and operational synergies. Its value creation model is based on partnering closely with management teams to implement long-term, sustainable growth strategies in a region with increasing private equity activity and consolidation opportunities.

Pacific Avenue Fund II is a buyout fund managed by Pacific Avenue Capital Partners, focused on complex corporate carve-outs and operationally intensive situations in the middle market. The fund leverages Pacific Avenue’s experience in building standalone businesses from non-core divisions of large corporations. The fund closed with over $1.65 billion in commitments, raised in a single fundraising cycle completed in under four months. This swift and oversubscribed raise reflects strong investor confidence in the firm’s track record and its differentiated strategy during a time when capital raising has been generally more challenging across private equity. Fund II includes a dedicated European sidecar of over €100 million to pursue cross-border carve-outs and platform investments. This reflects the firm’s growing international footprint, with operations and deal sourcing capabilities in both Los Angeles and Paris. Backers of the fund include a diverse set of institutional investors such as public pensions, consultants, endowments, insurance companies, funds of funds, and family offices. The fund was advised by Lazard (placement agent) and Weil, Gotshal & Manges LLP (legal counsel). With Fund II and its sidecar, Pacific Avenue now manages approximately $3.8 billion in total assets.

Pacific Equity Partners (PEP) is the seventh flagship buyout vehicle, Fund VII, in 2024 with a target size of A$3 billion. The fund held a first close at over A$1.5 billion in April 2024, reflecting strong demand from both existing and new investors.:contentReference[oaicite:74]{index=74} Fund VII continues PEP’s strategy of acquiring mid-to-large market businesses in Australia and New Zealand that have strong market positions in growing and defensible sectors. The fund aims to double the profits of its portfolio companies over the investment period through operational improvements and strategic growth initiatives.:contentReference[oaicite:77]{index=77} The fund targets a gross internal rate of return (IRR) exceeding 20% and a multiple of capital (MoC) of 2.0x over a 10-year horizon. PEP's approach involves close collaboration with management teams to drive transformational profit improvements, leveraging its extensive experience in the Australasian private equity market.</p

Pemberton Asset Management has closed its Mid-Market and Senior Loan Fund with €6.1 billion in committed capital, part of an €8.4 billion fundraising round that also includes its €2.3 billion Strategic Credit Fund III. This multi-strategy platform is designed to meet the capital needs of private equity sponsors and mid-market companies across Europe through flexible, senior-secured financing. The Mid-Market strategy targets asset-light businesses with strong cash flows and EBITDA between €15 million and €75 million. These companies generally have professional shareholders, experienced management teams, and operate in resilient, service-oriented industries. The Senior Loan strategy supports larger firms with EBITDA from €20 million to €100 million, offering conservative bank-style financing through senior secured loans ranging from €50 million to €250 million. Sector focus includes technology, outsourced business services, biotech, and life sciences—industries with strong contractual revenues and track records. The fund emphasizes stable, floating-rate returns while targeting core European economies such as France, Germany, the UK, Benelux, Nordics, and Southern Europe.

Peninsula Fund VIII is a closed-end mezzanine fund managed by Peninsula Capital Partners, launched in 2023. It operates as a limited partnership domiciled in Delaware, with its headquarters in Southfield, Michigan. The fund specializes in structured finance, particularly subordinated and mezzanine debt, focusing on lower middle-market companies in North America. It typically supports leveraged recapitalizations, management buyouts, and sponsor-backed acquisitions, offering flexible capital solutions. Peninsula Fund VIII was registered through a Form D filing on September 7, 2023, with a total offering amount of up to $450 million. It is managed by Peninsula Fund VIII Management LLC, a Michigan-based entity formed in August 2023, also headquartered in Southfield. The fund is part of the Peninsula Capital Partners family, a firm founded in 1995 and headquartered in Michigan. Peninsula has a long-standing track record in mezzanine financing and structured equity for U.S.-based companies. Notably, the New York State Teachers’ Retirement System committed $100 million to this fund in 2023.

The fund is the flagship eighth buy‑out vehicle of global private equity firm Permira, raising €16.7 billion in commitments and exceeding its €15 billion target. Permira VIII targets investing in market‑leading businesses that benefit from long‑term structural and resilient growth drivers, by partnering with outstanding entrepreneurs and management teams to scale their operations for the long term. The strategy focuses on four core sectors of expertise — Technology, Consumer, Healthcare and Services — and uses Permira’s global network and sector‑aligned value‑creation teams to drive operational improvement, thematic growth and a values‑based investing lens (including climate, gender diversity and governance targets). With a geographically global mandate, the fund will invest primarily in Europe and North America with selective exposure to Asia, targeting companies where technology is, or will become, a key growth component.

Quadria Capital Fund III is a growth-stage private equity vehicle focused on transforming healthcare systems across South and Southeast Asia. With $1.07 billion in commitments, the fund aims to build a diversified portfolio of approximately 10 market-leading companies, taking both significant minority and majority stakes. The fund has already deployed nearly 40% of its capital, including investments in Aragen Life Sciences, NephroPlus, and Maxivision Eye Hospital.The fund targets sectors such as healthcare delivery, life sciences, medical technology, and associated healthcare services. It seeks to invest in companies that provide high-quality, affordable healthcare solutions, leveraging technology and innovation to address the growing demand in the region. Quadria Capital's strategy includes partnering with exceptional healthcare businesses to enhance their impact and scale, while generating superior returns for investors.Quadria Capital Fund III has attracted a diverse group of investors, including sovereign wealth funds, asset managers, strategic corporates, and impact investors from North America, Europe, the Gulf Cooperation Council, and Asia. The fund's focus on healthcare transformation aligns with the increasing need for accessible and affordable healthcare services in rapidly growing markets.

Located in Amstelveen (Netherlands), Revo Capital Fund III is a venture capital fund managed by Revo Capital. Sectors of interest of the fund are: fintech, gaming, information technology, health tech, clean tech, insure tech, DevOps, marketplaces, martech, big data, cybersecurity, and artificial intelligence and machine learning sectors. The fund invests in global companies or in companies that have global businesses. Companies must be based in Eastern Europe, Turkey or the Baltics. The fund will aim for a first close of between $50 and $60 million in March, and targets $100 million, with a cap at $150 million. Revo plans to invest in over 25 seed to Series B startups, typically starting with up to $5 million per company and allocating up to $10 million with follow-ons. The firm also carved out a "Seed Pocket" for smaller initial checks of $250,000–500,000 in promising pre-seed and seed-stage startups.

Roark Capital Partners VII is the flagship private equity vehicle of Roark Capital, targeting $5 billion to fuel its strategy of investing in franchise and multi-location consumer-facing businesses. The fund builds on Roark’s extensive experience in the consumer, services, and franchise sectors, where it has backed brands such as Arby’s, Dunkin’, and Subway. With more than half of its target already raised, Fund VII reflects robust investor confidence in Roark’s disciplined buy-and-build approach. The fund’s core strategy is centered around acquiring platform businesses with strong brand equity and accelerating growth through consolidation and operational improvement. Roark specializes in supporting management teams in scaling their networks, improving unit economics, and expanding footprints across geographies. Fund VII will continue this strategy with a particular focus on multi-brand platforms and growth-stage operators with potential for franchising. Roark Capital aims to deploy capital through control-oriented buyouts, platform acquisitions, and select growth partnerships. Target companies typically exhibit predictable cash flows, high customer retention, and potential for franchise replication. The fund also allows for meaningful add-on activity to bolster existing platforms, with a focus on building category leaders in fragmented industries. Fund VII reinforces Roark’s positioning within the large-cap private equity space. As fundraising continues, the firm is expected to pursue investments across North America, leveraging its operational playbook, brand development expertise, and longstanding LP relationships. The vehicle is designed to generate value through scale, network effects, and the continued expansion of its consumer and franchise-driven ecosystem. The fund aims to partner with strong operating teams, acquire businesses with predictable cash‑flows, scalable platforms and well‑positioned brands, and drive long‑term value creation through operational improvement and growth initiatives. With approximately US$5 billion in commitments, the fund targets companies typically generating revenues from around US$20 million up to US$5 billion or more, and EBITDA from roughly US$10 million up to US$500 million or above. The principal geographic focus is North America, with select international franchise‑oriented opportunities, and sectors include restaurants, health & wellness, fitness, youth/education services, consumer products and business services.

The SOSV V fund is focused on deep tech startups in human and planetary health, with a focus on decarbonization and re-industrialization. The fund will invest in startups in the health sector, ranging from therapeutics to medical devices, as well as companies working on climate change solutions. SOSV operates startup program facilities in New York City, Newark, and San Francisco, supporting about 80 startups per year. The fund's limited partners include corporates, sovereign wealth funds, institutional investors, and private family offices around the world. The fund closed at $306 million on April 16th, 2024. SOSV invests starting at the pre-seed stage and continues through series seed, A, and later stages, resulting in about 200 investments per year. The fund tracks top portfolio startups in its annual Climate Tech 100 and Human Health 100 lists, which include companies working on climate solutions and health-related technologies. The fund also invests in facilities and equipment to help deep tech founders develop and de-risk their technologies. It operates in 40 countries and has founders representing 75 nationalities. The portfolio includes startups with 33% of companies having at least one female founder. The fund partners with other co-investors and has received support from venture firms and early-stage investors who have contributed to the successful launch of startups. The fund's emphasis on decarbonization and re-industrialization highlights its commitment to addressing climate change and creating positive change for humanity. The fund aims to bring power and expertise to the fight against climate-driven issues and loss of life.

Silver Lake Partners VII is a growth private equity fund managed by Silver Lake. The final close on Silver Lake Partners VII at $20.5 billion in capital commitments marks a continuation of the firm's global leadership in large-scale technology investing. Over the past five years, Silver Lake has raised $47 billion, with a focus on creating value through partnerships with exceptional founders and management teams to build and grow great companies driven by technology at scale. Silver Lake invests across the spectrum of the global technology sector and in technology-enabled businesses in verticals including sports and live events, media and entertainment, e-commerce, financial services, and health care. Their portfolio of companies represents more than $1 trillion of cumulative enterprise value, with a mission to make highly selective and impactful investments that have the potential to generate exceptional performance. Recent investment activities include the successful completion of a public tender offer to acquire Software AG for approximately $2.6 billion, take privatizations, and equity re-investments in companies such as Qualtrics, Vantage Data Centers, and Endeavor. These strategic transactions demonstrate Silver Lake's commitment to making significant investments across various sectors and geographic regions. Investors in Silver Lake Partners VII include public and corporate pension funds, sovereign wealth funds, insurance companies, endowments, foundations, funds of funds, family offices, technology industry leaders, and individual investors across the Americas, Asia-Pacific, and EMEA.

Sixth Street Opportunities Partners VI is a flexible, all-weather investment vehicle that seeks to capitalize on complex, high-value opportunities across the capital structure. The fund focuses on control-oriented transactions, asset opportunities, and corporate dislocations, employing a thematic and actively managed approach. The strategy is designed to provide downside protection while targeting attractive risk-adjusted returns. Investments may include control or minority equity, preferred equity, debt, or hybrid instruments, tailored to the specific needs of each opportunity. Sixth Street leverages its deep sector expertise and global platform to source and execute investments that are often complex and require bespoke solutions. The fund aims to deliver value through active management and strategic partnerships.

Sonder Futures II is a venture capital fund managed by Sonder Capital. The firm is based in San Carlos, California. The fund focuses on early stage investments in healthtech, medical devices and diagnostics companies. The firm invests in Seed, Series A and Series B rounds. The firm's portfolio companies include Spirair, BRIUS Technologies, Ziteo, and Neptune Medical, reflecting its focus on the healthcare and medical technology sectors. Sonder Capital's network of limited partners is global, including industry leaders, high-net-worth individuals, and leading family offices, indicating a broad geographic scope for potential investments.

StepStone Group Inc. has closed its fourth Tactical Growth Fund, STGF IV, with $705 million in capital commitments. The fund drew investments from sovereign wealth funds, public pensions, superannuation funds, funds-of-funds, family offices, and private wealth platforms. STGF IV partners with leading growth equity sponsors to back founder-led businesses in the technology and healthcare sectors. These companies typically operate outside the traditional VC ecosystem and are characterized by rapid topline growth, strong profit margins, capital efficiency, and low leverage. The fund is managed by StepStone’s Venture Capital and Growth Equity Team, which deploys around $5.5 billion annually. STGF IV complements buyout and venture strategies by using a range of approaches such as direct co-investments, continuation vehicles, and secondary transactions.

Strategic Value Special Situations Fund VI is the latest flagship fund from SVPGlobal, targeting distressed and special situation investments worldwide. The fund is designed to identify mispriced or underperforming credit and equity opportunities, focusing on companies experiencing operational or financial distress. With a flexible mandate, the fund invests across the capital structure—including debt, equity, and hybrid instruments—tailoring its approach to the unique needs and dynamics of each situation. This adaptability allows SVPGlobal to pursue opportunities across industries and regions, optimizing for value creation and downside protection. The strategy emphasizes hands-on value enhancement. Fund VI leverages SVPGlobal’s deep expertise in restructuring, turnaround execution, and stakeholder negotiation to unlock trapped value in distressed businesses. The fund often takes an active role in governance and strategic decision-making to guide portfolio companies toward recovery and growth. Strategic Value Special Situations Fund VI continues SVPGlobal’s legacy of producing strong returns through contrarian investing, capitalizing on inefficiencies in global credit markets, particularly during periods of volatility or economic transition.

TDK Ventures Fund 3 is a $150 million venture capital fund launched in April 2025 by TDK Corporation's corporate venture-capital subsidiary, TDK Ventures, Inc. The fund focuses on investing in early-stage deeptech startups that are poised to drive significant advancements in technology and sustainability. Building upon the success of its previous funds, Fund 3 aims to catalyze the next generation of iconic companies by providing not only capital but also strategic support through TDK's extensive global network. This includes access to TDK's R&D, manufacturing capabilities, and market channels, enabling startups to scale efficiently and effectively. Fund 3 continues TDK Ventures' mission to invest in transformative technologies that align with global megatrends, contributing to TDK's long-term vision of sustainable growth and innovation.

Fund II of TELEO Capital builds on the firm’s operationally‑focused private equity platform that specializes in corporate carve‑outs, founder‑led companies and under‑performing assets in the lower middle market. With commitments of USD 350 million at its hard cap, the fund targets control investments in businesses that can benefit from TELEO’s dedicated team of operational professionals, proven carve‑out playbook, and focus on speed and certainty of execution.The investment strategy emphasises enterprise software, tech‑enabled services and healthcare IT, acquiring mission‑critical divisions of larger corporations where TELEO can strengthen go‑to‑market, accelerate product development (including adoption of AI) and enhance operational efficiency.Typical target companies are in the lower middle market — for example, recurring or re‑occurring revenue models, scalable cost structures, asset‑light business models, profitability not strictly required — with enterprise values up to about USD 100 million and equity checks in the USD 10‑50 million range.Geographically, while based in the U.S., TELEO Capital looks broadly across North America (and may consider Europe/Australia) to deploy its platform‑driven approach in complex carve‑out transactions and special situations where operational value creation is key.

The TIDE Africa Fund II of TLcom Capital has a target investment of $154 million in seed and Series A companies, making it Africa's largest investor across these stages. It attracted participation from over 20 limited partners, including notable investors such as the European Investment Bank (EIB), Visa Foundation, Bertelsmann, and AfricaGrow, a joint venture between Allianz and DEG Impact. TLcom Capital focuses on traditional sectors like fintech, mobility, agriculture, healthcare, education, and commerce, prioritizing early-stage opportunities, particularly at the seed and Series A stages, while also considering opportunistic deals at growth and later stages. It generally backs 20 to 25 companies, aiming for 10x to 20x returns on potential investments and expects to achieve 3x to 4x returns on an aggregate basis. The fund is also improving its risk by backing repeat founders, like Sim Shagaya, Etop Ikpe, and Grant Brooke, as well as investing earlier in deals and women-led startups through FirstCheck Africa. As of April 2024, TLcom has backed six companies from its new fund, with initial investments ranging from $1 million to $3 million, and aims to target the Big Four markets, adding Egypt and South Africa as destinations of its capital. By doing so, TLcom expects to achieve tangible returns and drive the overall growth of the African tech ecosystem. The fund will invest between USD 500 000 as the minimum initial investment in seed stage opportunities, to USD 15 million over the life cycle of the investment, with an expected average of around USD 7-9 million per successful company.From the USD 5 million, 2 million will be dedicated to female entrepreneurs through a co-investment agreement with First Check Africa. It is a 10-year life Fund of which 5 years investment and 5 years divestment period which can be extended by 1 year each.

TLG Africa Growth Impact Fund II (AGIF II) is a $200 million private credit fund managed by TLG Capital, established to address the financing gap faced by African SMEs. With a strategic focus on supporting businesses that are financially viable but currently under strain, the fund aims to unlock their growth potential through tailored credit solutions and advisory support. The fund reached its first close at $75 million, backed by a consortium of international development finance institutions. Anchor commitments came from the International Finance Corporation (IFC), alongside Swedfund, Norfund, Bpifrance, and the UK’s Foreign, Commonwealth & Development Office (FCDO), through its Manufacturing Africa program. This collective backing reflects confidence in the fund’s approach and impact-oriented strategy. AGIF II works closely with local financial institutions to co-finance SMEs, often leveraging guarantees from local banks to reduce investment risk. This collaboration ensures capital reaches underserved yet promising companies, enabling them to restructure debt, expand operations, and maintain employment during challenging macroeconomic conditions. In addition to financial support, AGIF II offers value-added strategic and operational advisory services. The fund partners with leading advisory firms such as McKinsey, BDO, ESS, and Ndarama Works to help portfolio companies transform their business models and strengthen resilience. This dual approach of capital and capacity-building is central to AGIF II’s impact thesis. The fund prioritizes inclusive and sustainable development by focusing on investments in the UN’s least developed countries, promoting gender equity, local ownership, and industrialization. AGIF II embodies a strong belief in achieving competitive financial returns while delivering meaningful development outcomes.

TPG Growth VI, L.P. is a growth equity investment vehicle launched in 2023 by TPG Growth, aimed at partnering with high-momentum companies at the expansion stage. As a feeder fund, the Cayman Islands entity channels capital into the Master Fund, providing exposure to TPG’s global pipeline of growth-stage opportunities while leveraging its operational and sector expertise. The fund focuses on making 20 to 25 investments, targeting up to $300 million in developed markets and up to $150 million in India per deal. It deploys capital across industries including software & enterprise technology, internet, digital media & communications, healthcare, and business services, sectors where TPG Growth has demonstrated strong conviction and value-creation capabilities. With its base in Fort Worth, the fund’s structure as a feeder enhances its accessibility to international investors while maintaining a disciplined investment horizon. The fund’s development mirrors TPG’s 2023 strategy, including ambitious fundraising goals and confidence in the potential of growth equity amid evolving market conditions. Investment commitments are being actively raised, with approximately $2.08 billion raised in updated filings as of September 25, 2024, reflecting strong investor interest. The fund’s long-term orientation, diversified industry targeting, and geographical breadth suggest a strategic approach to capturing growth opportunities across markets.

TPG Partners X is the latest flagship buyout fund from TPG, aiming to raise $13 billion. This target reflects a strategic adjustment from the $14–$15 billion goal of its predecessor, TPG Partners IX, which closed at just over $12 billion. The revised target acknowledges the current fundraising challenges in the private equity landscape, influenced by factors such as increased interest rates and market volatility. The fund is designed to make significant investments, with plans to write checks of approximately $1 billion per deal. TPG Partners X will focus on acquiring businesses in the healthcare, information technology, services, and consumer sectors. This approach aligns with TPG's strategy to capitalize on market dislocations and invest in sectors with strong growth potential. Despite the headwinds in the fundraising environment, TPG continues to demonstrate resilience and adaptability. The firm holds $57 billion in deployable capital across various investment classes and has recently made notable investments, including the $2.2 billion take-private of fintech firm AvidXchange and the acquisition of digital infrastructure investment firm Peppertree Capital Management. These moves underscore TPG's commitment to identifying and seizing investment opportunities in a dynamic market.

Building on the success of its predecessors, TPG Rise Fund IV aims to invest in growth-stage, high-potential, mission-driven companies that align with the United Nations Sustainable Development Goals (UN SDGs). The fund focuses on sectors where positive impact and financial performance are intrinsically linked. Utilizing the proprietary Impact Multiple of Money (IMM) framework developed by Y Analytics, TPG Rise Fund IV seeks to quantify the social and environmental impact of its investments. This methodology ensures that each investment delivers measurable outcomes, such as increased access to education, healthcare, and financial services, or significant reductions in greenhouse gas emissions. The fund is expected to continue TPG's strategy of partnering with companies that offer scalable solutions to global challenges, leveraging the firm's deep sector knowledge, operational resources, and global experience to drive value creation and help companies reach their full potential.

The fund Tenex Capital Partners IV, L.P. is a middle market buyout private equity fund that targets small and middle market fundamentally sound but operationally underperforming companies in North America within the sectors of Diversified Industrials, Business & Tech Services, and Healthcare. The fund seeks to invest in companies that are family owned, private equity owned, or corporate carve-outs and aims to drive investment performance through operational improvements. The fund will seek to invest in 16 to 18 portfolio companies over 5 years, targeting equity investments of $50 million to $100 million each. Tenex IV is targeting a majority equity ownership in its portfolio companies, which are typically underperforming due to underinvestment and inefficient management of operating assets. The fund intends to bring these companies from below market in their sectors to average, operating in desirable end markets with strong product or service offerings. Geographically, the fund focuses on North America and has a target of 60-80% of its allocation in buyout strategies, with the remainder in venture capital, growth equity, and opportunistic credit investments. Tenex IV is managed by Tenex Capital Management.

Thoma Bravo Fund XVI is the latest flagship buyout vehicle from Thoma Bravo, a leading software-focused private equity firm. Launched in late 2023, the fund successfully closed in mid-2025 with $24.3 billion in capital commitments, making it the largest private equity fund globally for 2024 or 2025. This achievement underscores investor confidence in Thoma Bravo's strategy of acquiring and scaling enterprise software companies. The fund targets 12 to 15 platform investments, each with equity commitments ranging from $900 million to $4 billion. Target companies typically have enterprise values between $2.5 billion and $13 billion. Thoma Bravo employs a "buy and build" strategy, seeking to enhance operational efficiency and drive growth through strategic acquisitions. Fund XVI focuses on sectors such as infrastructure software, cybersecurity, fintech, and enterprise applications. Geographically, the fund targets investments primarily in North America (85%) and Europe (15%). Thoma Bravo's approach involves partnering with existing management teams to implement best practices and accelerate value creation.

TowerBrook Investors VII represents the next flagship vehicle of TowerBrook Capital Partners, aimed at building on the firm’s trans‑Atlantic private equity platform and longstanding focus on buy‑out investments. The fund is expected to deploy capital in companies where the firm can partner with strong management teams to drive operational transformation, improve market positioning, and build resilient service‑led businesses. The strategy reflects TowerBrook’s identity as a “modern value investor” focused on services businesses across North America and Europe.In terms of geography, the fund is expected to invest in mid‑to‑large companies in both Europe and North America, acknowledging TowerBrook’s dual‑headquarters in London and New York and the firm’s recent push to deepen its footprint across Europe, the Middle East and the Nordics.While the fund is still being raised, the deployment strategy is anticipated to emphasise control‑oriented capital (and potentially structured or minority investments where appropriate) in companies with proven business models and strong management teams. The value creation thesis will leverage TowerBrook’s operational capabilities, its emphasis on responsible ownership (including ESG integration) and a disciplined approach to transaction structure and transformation.

Town Hall Ventures IV is the fourth flagship fund from Town Hall Ventures, a mission‑oriented venture firm focused on transforming healthcare delivery in underserved U.S. communities. With a capital target in the hundreds of millions, THV IV seeks to extend the firm’s track record of backing AI‑driven, technology‑enabled care models that reduce cost, improve outcomes, and expand access. This fund builds on Town Hall’s deep roots in both policy and healthcare systems, leveraging the firm’s relationships with payers, health systems, and public agencies to accelerate go-to-market execution for portfolio companies. THV IV allocates capital across stages, deploying initial investments but retaining optionality for follow-on support, enabling companies to scale over multiple rounds. The fund targets startups that marry mission and scale — companies that can serve large, diverse patient populations while maintaining cost discipline and strong unit economics. THV IV investors will look for management teams that understand the complexity of Medicaid, Medicare, social determinants of health, and care delivery in fragmented geographies. In execution, Town Hall Ventures IV will seek to invest in 20‑40 companies over its lifecycle, with average initial investments in the $3M to $30M range. The fund will emphasize sectors such as AI for clinical automation, value‑based provider platforms, home-based care, mental health, and payer enablement — always with a lens toward equity, cost reduction, and access.

Veritas Capital Fund IX is the latest flagship private equity fund from Veritas Capital, a New York-based firm specializing in investments at the intersection of technology and government. Launched in 2024, the fund has raised over $13 billion, exceeding its initial $10 billion target by 25%. This growth reflects strong investor confidence in Veritas's strategy of acquiring and transforming companies that provide critical products and services to government and commercial clients. The fund focuses on buyouts of mature, mid-sized companies primarily in the United States. Target sectors include aerospace and defense, healthcare IT, cybersecurity, and government services—industries characterized by high barriers to entry, long-term contracts, and consistent demand. Veritas aims to enhance these companies' value through strategic initiatives, operational improvements, and technological innovation. Veritas Capital Fund IX has attracted commitments from a diverse group of institutional investors, including public pension funds and insurance companies. The fund's strategy builds on the success of its predecessor, Fund VIII, which closed in 2022 with $10.65 billion in commitments. Veritas's proven track record in delivering strong returns positions Fund IX to capitalize on opportunities in sectors vital to national infrastructure and security.

Vivo Opportunity Fund III is the latest iteration of Vivo Capital's evergreen equity fund, structured in three-year investment cycles. With over $740 million in commitments, the fund continues its focus on small- and mid-cap biotechnology and life sciences companies, particularly those developing or commercializing novel therapies targeting unmet medical needs. The fund primarily backs preclinical and clinical-stage companies, aiming to realize value through scientific breakthroughs and pivotal clinical milestones. Vivo Capital employs a hybrid strategy that combines public market investing with a venture capital approach, leveraging the firm’s technical expertise to identify high-potential healthcare assets. Vivo has a strong track record, with previous Opportunity Funds supporting companies that have reached major inflection points, such as FDA approvals or strategic acquisitions. Noteworthy examples include investments in Verona Pharmaceuticals, Geron Corporation, and Soleno Therapeutics.

Warburg Pincus Global Growth XV marks the firm’s latest flagship growth vehicle, aiming for approximately $17 billion in capital commitments. Following the record‑breaking $17.3 billion close of Global Growth XIV in 2023, this new fund continues the firm’s trajectory of scaling its global growth‑stage investment mandate. The fund will deploy capital across sectors including technology, healthcare, financial services, industrial & business services, real estate, and energy. It will focus on high‑growth, mid‑to‑late stage companies with operational traction and scalable business models across the Americas, Europe, Asia, and other global markets. Ticket sizes are expected to range from $175 million to $200 million, targeting companies with revenue of $50 million to well over $500 million, positive EBITDA, and valuations at growth‑equity multiples. The fund looks to partner with strong management teams and invest with conviction while maintaining sector and geographic diversification. As part of Warburg Pincus’s disciplined global growth strategy, Global Growth XV will build on strong past performance and the firm’s deep operational support model. With a diversified LP base—from global institutional investors to high‑net‑worth and family offices—it continues the firm’s thesis‑driven, long‑term partnership model across cycles.